Life expectancy in HIV-positive people in the US still lags 13 years behind HIV-negative people

Smoking is biggest ascertainable risk factor
Julia Marcus presenting at CROI 2016. Photo by Liz Highleyman,
This article is more than 8 years old. Click here for more recent articles on this topic

A study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) comparing life expectancies of HIV-positive and HIV-negative people within the Kaiser Permanente health insurance system has found that although life expectancy in HIV-positive people has improved, life expectancy at age 20 remains 13 years behind that of matched HIV-negative people. This 13-year gap did not improve between 2008 and 2011, the last year of follow-up in this cohort study.

The study was also able to compare life expectancies in both HIV-positive and HIV-negative people in the Kaiser system with life expectancies in the US general population. Life expectancy is two years lower in the US general population that in the HIV-negative group in Kaiser, and the difference is greater in some groups, notably five years in men. At least part of this difference will be due to HIV, though part will also be due to differences in health coverage.

“In addition to timely ART initiation, risk-reduction strategies such as smoking cessation may further narrow the survival gap." Julia Marcus

The researchers also looked at risk factors for mortality and were able to calculate life expectancy if these were absent. Starting antiretroviral therapy (ART) early, not having hepatitis B or C, and not having a history of drug and alcohol problems all raised life expectancy; but the biggest difference was due to smoking. Nonetheless, even HIV-positive people who had never smoked had a life expectancy over five years lower than HIV-negative people.

More details

The study looked at mortality rates in 24,768 HIV-positive people within the Kaiser Permanente system and compared them with ten times that number of HIV-negative people (257,600) also in the system between the years 1996 and 2011. The two groups were matched for age (31 at entry to the study) and gender (91% male). Deaths were ascertained from death certificates and social security records so could be traced even if people left the Kaiser system.



In a case-control study, a process to make the cases and the controls comparable with respect to extraneous factors. For example, each case is matched individually with a control subject on variables such as age, sex and HIV status. 

equivalence trial

A clinical trial which aims to demonstrate that a new treatment is no better or worse than an existing treatment. While the two drugs may have similar results in terms of virological response, the new drug may have fewer side-effects, be cheaper or have other advantages. 


A mental health problem causing long-lasting low mood that interferes with everyday life.

occupational exposure

Exposure to HIV as a result of work (job) activities. Exposure may include accidental exposure to HIV-infected blood following a needlestick injury or cut from a surgical instrument

They were matched approximately for ethnicity: 56% of HIV-positive and 44% of HIV-negative people were white, 21% versus 25% were black, and 18% versus 10% were Hispanic. Ethnicity was less well-recorded in HIV-negative people.

Forty-five per cent of the HIV-positive people had ever smoked versus 31% of the HIV-negative; 21% of positive versus 9% of negative had ever had drugs or alcohol problems; and 12% versus 2% had ever had hepatitis B or C.

In the HIV-positive people, 75% were men who acquired HIV through sex with other men; 16% were heterosexual men and women; 7% got HIV through injecting drug use; and 2% through other routes such as occupational exposure. Forty-six per cent were already on ART when they joined the Kaiser cohort, while another 40% started during their period in the study. One in three (35%) did not start ART until their CD4 count was below 200 cells/mm3, while 18% started at CD4 counts over 500 cells/mm3.

The cohort study starts at 1996, which was just before ART became generally available, so there was a rapid decrease in mortality of HIV-positive people in the first two years of the study; it then continued to decline at a slower rate from 1998 onwards. In 1996-97 the death rate in HIV-positive people was 7.08% a year. By 2011 this had declined to 1.05% a year. The equivalent rates in HIV negative people were 0.44% a year in 1996-97 and 0.38% a year in 2011.

What did this do to life expectancy? In 1996-97 the life expectancy at age 20 of an HIV-positive person was 19 years, in other words they could only expect to live, on average, in the absence of any improvement in treatment, till they were 39. By 2011, this had improved to 53 years, i.e. death on average at 73.

For HIV-negative people, life expectancy at age 20 in 1996-97 was 63 years; by 2011 this had improved to 65 years, i.e. death on average at 85.

In HIV-positive women, life expectancy improved slightly less than it did on men. For subgroups, instead of contrasting 1996-97 with 2011, the researchers contrasted life expectancy during the whole period between 1996 and 2007 with life expectancy from 2008-2011.

For HIV-positive men, life expectancy at age 20 was 37 more years in the 1996-2007 period and 51 years in 2008-2011; for women it was 38 years between 1996 and 2007 and 49 years in 2008-2011.

The increase in life expectancy in white people was the same as it was in men. In black people it was lower during both periods and did not improve as much as in white people (38 years at age 20 in 1997 to 2007 and 46 in 1998-2001 – this was pretty much the same increase as in people who inject drugs); while Hispanic people did rather better with an improvement from 39 to 52 years. In gay men it improved from 40 to 51 years.

One interesting aspect of this study is that death rates and life expectancy in HIV-positive people has tended to be compared with the general population’s figures. But of course people with HIV form part of the general population. Thus, taken over the whole study period, life expectancy in HIV-positive people at age 20 was 49 years; in HIV-negative people it was 62 years; and in the US general population it was 60 years. This means that if the Kaiser Permanente HIV-negative population resembles the HIV-negative US general population, then HIV reduces life expectancy in the US general population by two years.

In subgroups, the difference was bigger: in men the gap between HIV-negative and general-population life expectancy was five years, in black people three years, and in Hispanic people six years. However, Kaiser’s users are not likely to resemble the general population, so the actual reduction in life expectancy due to HIV in the general population is likely to be lower than this.

There still remains a gap of 13.1 years between HIV-positive and HIV-negative life expectancy in this study, and this did not improve between 2008 and 2011. The researchers then looked at factors that might narrow this gap. In people who started ART at CD4 counts over 500 cells/mm3, the life expectancy gap between them and HIV-negative people was 7.9 years, i.e. it added 5.2 years to an HIV-positive person’s life expectancy. Not having had hepatitis B or C added 5.9 years; not having had problems with drugs or alcohol added 6.5 years; and not having ever smoked added 7.7 years. This still left a life expectancy gap of 5.4 years, however.

Julia Marcus of Kaiser, presenting, commented: “In addition to timely ART initiation, risk-reduction strategies such as smoking cessation may further narrow the survival gap." She said they would consider looking at other factors that might impact on life expectancy such as depression, which is more common in people with HIV.

She added: “Future studies should determine if this survival gap persists in more recent years, and if so, identify factors that may contribute.”


Marcus JL et al. Narrowing the gap in life expectancy for HIV+ compared with HIV- individuals. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, abstract 54, 2016. 

View the abstract on the conference website.

View a webcast of this session on the conference website.